STING-associated vasculopathy with onset in infancy

A source-backed guide to STING-associated vasculopathy with onset in infancy: symptoms, causes, diagnosis, care, urgent warning signs, and practical questions.

Health categoryHeart and blood vessels

Start here

Overview

Clinical references note that STING-associated vasculopathy with onset in infancy (SAVI) is a disorder involving atypical inflammation throughout the body, especially in the skin, blood vessels, and lungs. In practice, Inflammation normally occurs when the immune system sends signaling molecules and white circulating blood cells to a site of injury or disease to fight microbial invaders and help with tissue repair. Evidence summaries report that Excessive inflammation damages the body's own cells and tissues. This overview explains the usual pattern of STING-associated vasculopathy with onset in infancy; it cannot determine whether one individual has the condition.

  • Clinical references note that STING-associated vasculopathy with onset in infancy (SAVI) is a disorder involving atypical inflammation throughout the body, especially in the skin, blood vessels, and lungs. In practice, Inflammation normally occurs when the immune system sends signaling molecules and white circulating blood cells to a site of injury or disease to fight microbial invaders and help with tissue repair. Evidence summaries report that Excessive inflammation damages the body's own cells and tissues. This overview explains the usual pattern of STING-associated vasculopathy with onset in infancy; it cannot determine whether one individual has the condition.
  • Identifying STING-associated vasculopathy with onset in infancy starts with the clinical pattern and a focused examination. A clinician chooses tests to answer a specific question, then interprets results alongside age, medicines, family history, exposures, and other conditions. No single investigation is appropriate for every person.
  • Care for STING-associated vasculopathy with onset in infancy depends on its cause, severity, organs involved, other health conditions, and the person's goals. Options can range from observation and symptom support to medicines, procedures, rehabilitation, or specialist follow-up. The safest plan is individualized; prescribed care should not be changed because another person had a different experience.

Do not wait for a website to decide

  • Call emergency services for new chest pressure, severe breathlessness, collapse, or a sudden cold sweat with pain spreading to the arm, jaw, or back.
  • Seek prompt professional assessment when symptoms are new, persistent, or clearly worsening.

People can experience it differently

What symptoms can occur?

Evidence summaries report that the clinical features of SAVI begin in the first few months of life, and most are related to difficulties with blood vessels (vasculopathy) and damage to the tissues that rely on these vessels for their blood supply. For patients and families, an important point is that affected infants develop areas of severely damaged skin (lesions), particularly on the face, ears, nose, fingers, and toes. Clinical references note that the skin problems, which worsen in cold weather, may lead to complications such as scarred ears, a hole in the body tissue that separates the two nostrils (nasal septum perforation), or fingers or toes that require amputation. In practice, affected individuals can also experience episodes of Raynaud phenomenon, in which the fingers and toes turn white or blue in response to cold temperature or other stresses. Symptoms can overlap with other illnesses, and their absence does not always rule the condition out.

Risk does not equal certainty

Causes and risk factors

What is known about the cause

Clinical references note that affected infants develop areas of severely damaged skin (lesions), particularly on the face, ears, nose, fingers, and toes. In practice, individuals with SAVI also have a purplish skin discoloration (livedo reticularis) caused by abnormalities in the tiny blood vessels of the skin. Evidence summaries report that they can also develop widespread lung damage (interstitial lung disease) that may lead to the formation of scar tissue in the lungs (pulmonary fibrosis) and difficulty breathing; these respiratory complications can become life-threatening. The cause of STING-associated vasculopathy with onset in infancy may be established, multifactorial, or still uncertain. Biological mechanisms, inherited factors, infections, exposures, medicines, and related health conditions are considered only when they fit the evidence. A general description should not be used to assign a personal cause.

Factors associated with higher risk

Evidence summaries report that STING-associated vasculopathy with onset in infancy (SAVI) is a disorder involving atypical inflammation throughout the body, especially in the skin, blood vessels, and lungs. Factors linked with STING-associated vasculopathy with onset in infancy differ by subtype and population. A clinician may consider age, family history, relevant exposures, medicines, and related conditions, but the importance of each factor varies. Risk changes probability; it does not confirm a diagnosis or predict one person's course.

Risk is not a diagnosis

Who is more likely to be affected?

Evidence summaries report that STING-associated vasculopathy with onset in infancy (SAVI) is a disorder involving atypical inflammation throughout the body, especially in the skin, blood vessels, and lungs. Factors linked with STING-associated vasculopathy with onset in infancy differ by subtype and population. A clinician may consider age, family history, relevant exposures, medicines, and related conditions, but the importance of each factor varies. Risk changes probability; it does not confirm a diagnosis or predict one person's course.

Tests answer specific questions

Common tests and what they show

  • Clinical assessment

    Identifying STING-associated vasculopathy with onset in infancy starts with the clinical pattern and a focused examination. A clinician chooses tests to answer a specific question, then interprets results alongside age, medicines, family history, exposures, and other conditions. No single investigation is appropriate for every person.

  • Purpose and limits of testing

    Tests should confirm a working diagnosis, assess severity, identify complications, or rule out an important alternative. Not every person needs every available investigation, and a result must be interpreted in context.

Clinical assessment

How is it diagnosed?

Identifying STING-associated vasculopathy with onset in infancy starts with the clinical pattern and a focused examination. A clinician chooses tests to answer a specific question, then interprets results alongside age, medicines, family history, exposures, and other conditions. No single investigation is appropriate for every person.

Professional assessment matters

What else can look similar?

Several disorders can resemble STING-associated vasculopathy with onset in infancy, and the useful comparison depends on the symptom pattern, age, timing, examination, medicines, exposures, and test findings. Similarity in a search result is not enough to distinguish them. A clinician should prioritize alternatives that are common, treatable, or dangerous to miss, then select only the investigations likely to change care.

Classification can guide care

Types, severity, or stages

Some people with STING-associated vasculopathy with onset in infancy are classified by cause, clinical type, severity, affected body system, or stage. These labels can guide testing, treatment, monitoring, and prognosis, but they are not interchangeable. Ask which classification applies, what evidence supports it, and whether it may change as more information becomes available.

Shared decisions

What are the treatment options?

Care for STING-associated vasculopathy with onset in infancy depends on its cause, severity, organs involved, other health conditions, and the person's goals. Options can range from observation and symptom support to medicines, procedures, rehabilitation, or specialist follow-up. The safest plan is individualized; prescribed care should not be changed because another person had a different experience.

Looking beyond today's visit

Outlook and follow-up

The outlook for STING-associated vasculopathy with onset in infancy varies with cause, severity, age at onset, organs involved, other health conditions, access to care, and response to treatment. Population averages cannot forecast one person's result. A more useful discussion sets measurable goals, identifies complications worth monitoring, and agrees on a date to reassess the plan.

Recognizing important change

Possible complications

Potential complications of STING-associated vasculopathy with onset in infancy depend on the disease mechanism, severity, delay before treatment, and effects of therapy. Follow-up aims to identify important change early without testing for every theoretical problem. Ask which two or three complications are most relevant, what warning signs they cause, and whether scheduled examination or laboratory monitoring is needed.

Practical support

Self-management

For STING-associated vasculopathy with onset in infancy, use the monitoring and follow-up plan agreed with the clinical team. Keep an accurate medicine list, note possible side effects, and record meaningful changes in symptoms or daily function. Not every case of STING-associated vasculopathy with onset in infancy can be prevented. Where modifiable risks or screening options exist, a clinician can help decide which steps are relevant. Appropriate follow-up and early review of new problems can reduce avoidable harm. Home observations are most useful when they support a clinical decision; repeated checking without a plan can increase anxiety and may still miss important change.

Long-term health

Living with the condition

Living with STING-associated vasculopathy with onset in infancy may affect energy, sleep, mobility, school, work, relationships, or emotional wellbeing, although the impact varies widely. Tell the care team what has become difficult rather than reporting test values alone. Ask which activities are safe, what support is available, and how progress will be measured. Reliable peer support can reduce isolation, but another person's diagnosis or treatment should not be copied as a personal plan.

Practical, evidence-based choices

Food and nutrition

There is no universal food plan that cures STING-associated vasculopathy with onset in infancy. Nutrition advice should reflect the condition, medicines, swallowing or digestive symptoms, kidney and liver function, allergies, weight goals, culture, and access to food. Avoid restrictive diets or supplements promoted as substitutes for diagnosis or treatment; discuss any product that could interact with prescribed care.

Advice may need adapting

Children, pregnancy, and older adults

Children, older adults, pregnant or breastfeeding people, and those with kidney, liver, immune, developmental, or multiple health conditions may experience STING-associated vasculopathy with onset in infancy differently. Test ranges, medicine doses, side-effect risks, and thresholds for urgent review can change in these groups. General information should therefore be checked against advice from a suitably qualified professional.

Separating evidence from assumptions

Common misconceptions

  • One symptom or online checklist can prove STING-associated vasculopathy with onset in infancy.

    Symptoms often overlap across conditions. Diagnosis depends on context, examination, and appropriate testing.

  • A treatment that helped another person is automatically safe for me.

    Benefits, risks, doses, and monitoring depend on the individual, other conditions, and medicines.

Use appointment time well

Preparing for care

Before an appointment about STING-associated vasculopathy with onset in infancy, write down when the problem began, how it has changed, what makes it better or worse, and how it affects ordinary activities. Bring previous reports, a full list of medicines and supplements, allergies, relevant family history, and two or three priorities. Ask what evidence supports the working diagnosis, which alternatives remain possible, what each test could change, and when follow-up should occur.

Care conversations

Questions to ask a health professional

  1. What findings support this diagnosis, and what important alternatives remain?
  2. Which tests are most likely to change the next decision?
  3. What are the realistic benefits, risks, and alternatives for each care option?
  4. Which changes require routine contact, prompt review, or emergency help?

Questions people often ask

10 common questions

What does STING-associated vasculopathy with onset in infancy mean?

Clinical references note that STING-associated vasculopathy with onset in infancy (SAVI) is a disorder involving atypical inflammation throughout the body, especially in the skin, blood vessels, and lungs. In practice, Inflammation normally occurs when the immune system sends signaling molecules and white circulating blood cells to a site of injury or disease to fight microbial invaders and help with tissue repair. Evidence summaries report that Excessive inflammation damages the body's own cells and tissues. This overview explains the usual pattern of STING-associated vasculopathy with onset in infancy; it cannot determine whether one individual has the condition.

What symptoms can occur with STING-associated vasculopathy with onset in infancy?

Evidence summaries report that the clinical features of SAVI begin in the first few months of life, and most are related to difficulties with blood vessels (vasculopathy) and damage to the tissues that rely on these vessels for their blood supply. For patients and families, an important point is that affected infants develop areas of severely damaged skin (lesions), particularly on the face, ears, nose, fingers, and toes. Clinical references note that the skin problems, which worsen in cold weather, may lead to complications such as scarred ears, a hole in the body tissue that separates the two nostrils (nasal septum perforation), or fingers or toes that require amputation. In practice, affected individuals can also experience episodes of Raynaud phenomenon, in which the fingers and toes turn white or blue in response to cold temperature or other stresses. Symptoms can overlap with other illnesses, and their absence does not always rule the condition out.

What causes STING-associated vasculopathy with onset in infancy?

Clinical references note that affected infants develop areas of severely damaged skin (lesions), particularly on the face, ears, nose, fingers, and toes. In practice, individuals with SAVI also have a purplish skin discoloration (livedo reticularis) caused by abnormalities in the tiny blood vessels of the skin. Evidence summaries report that they can also develop widespread lung damage (interstitial lung disease) that may lead to the formation of scar tissue in the lungs (pulmonary fibrosis) and difficulty breathing; these respiratory complications can become life-threatening. The cause of STING-associated vasculopathy with onset in infancy may be established, multifactorial, or still uncertain. Biological mechanisms, inherited factors, infections, exposures, medicines, and related health conditions are considered only when they fit the evidence. A general description should not be used to assign a personal cause.

Who may be more likely to develop STING-associated vasculopathy with onset in infancy?

Evidence summaries report that STING-associated vasculopathy with onset in infancy (SAVI) is a disorder involving atypical inflammation throughout the body, especially in the skin, blood vessels, and lungs. Factors linked with STING-associated vasculopathy with onset in infancy differ by subtype and population. A clinician may consider age, family history, relevant exposures, medicines, and related conditions, but the importance of each factor varies. Risk changes probability; it does not confirm a diagnosis or predict one person's course.

How do clinicians identify STING-associated vasculopathy with onset in infancy?

Identifying STING-associated vasculopathy with onset in infancy starts with the clinical pattern and a focused examination. A clinician chooses tests to answer a specific question, then interprets results alongside age, medicines, family history, exposures, and other conditions. No single investigation is appropriate for every person.

How is STING-associated vasculopathy with onset in infancy usually treated or managed?

Care for STING-associated vasculopathy with onset in infancy depends on its cause, severity, organs involved, other health conditions, and the person's goals. Options can range from observation and symptom support to medicines, procedures, rehabilitation, or specialist follow-up. The safest plan is individualized; prescribed care should not be changed because another person had a different experience.

Can STING-associated vasculopathy with onset in infancy be prevented or its risks reduced?

Not every case of STING-associated vasculopathy with onset in infancy can be prevented. Where modifiable risks or screening options exist, a clinician can help decide which steps are relevant. Appropriate follow-up and early review of new problems can reduce avoidable harm.

What should I record between appointments?

Keep a short dated record of symptoms, functional impact, medicines and side effects, relevant measurements, and questions. A consistent summary is usually more useful than a large amount of unstructured information.

When should someone with possible STING-associated vasculopathy with onset in infancy seek urgent help?

Use the warning signs near the top of this guide and any personal emergency plan. Severe new symptoms, rapid deterioration, collapse, confusion, major breathing difficulty, uncontrolled bleeding, or inability to remain safe require urgent assessment.

How can I make the next appointment more useful?

Before an appointment about STING-associated vasculopathy with onset in infancy, write down when the problem began, how it has changed, what makes it better or worse, and how it affects ordinary activities. Bring previous reports, a full list of medicines and supplements, allergies, relevant family history, and two or three priorities. Ask what evidence supports the working diagnosis, which alternatives remain possible, what each test could change, and when follow-up should occur.

Editorial boundaries

About this guide

Maintained by whocure content team

Purpose Health education and appointment preparation; not individual diagnosis or treatment.

Language status English content is maintained separately from the Chinese edition.